Colorectal Cancer (CRC) Terminated Phase 1 Trials for Trastuzumab (DB00072)

Back to Colorectal Cancer (CRC)

Also known as: Malignant Neoplasm of Colorectum / CRC, Colorectal Cancer / Colorectal Cancer / Cancer, Colorectal / CRC (Colorectal Cancer) / Colorectal, Cancer / Colo-rectal Cancer / Colorectal Cancers / A. Colorectal Cancer / Cancer Colorectal / Gastrointestinal Cancers - Colorectal / CRC / CRCS / Malignant colorectal neoplasm / Malignant neoplasm of cecum and/or colon and/or rectum / Malignant neoplasm of caecum and/or colon and/or rectum / Malignant neoplasm of cecum and/or colon and/or rectum (disorder) / Malignant neoplasm of large intestine / Malignant tumor of large intestine / Malignant tumour of large intestine / Malignant neoplasm of large intestine (disorder) / Malignant neoplasm of colon, unspecified / Malignant large intestinal neoplasm NOS / Cancer of large intestine / Malignant neoplasm of large intestine, NOS / Cancer of large bowel / CA - Cancer of large bowel / Colorectal neoplasms malignant / Malignant neoplasm of colon and/or rectum (disorder) / Large intestine carcinoma / Colorectal carcinoma / Colorectal cancer NOS

Indication	Status	Phase
DBCOND0031867 (Colorectal Cancer (CRC))	Terminated	1

clinicaltrials.gov Identifier	Title	Purpose	Drugs
NCT05395052	FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid Tumors	Treatment	Amivantamab (DB16695) Atezolizumab (DB11595) Avelumab (DB11945) Cetuximab (DB00002) Cyclophosphamide (DB00531) FT536 (DB28008) Fludarabine (DB01073) Human interleukin-2 (DB14865) Nivolumab (DB09035) Pembrolizumab (DB09037) Trastuzumab (DB00072)
NCT02318901	Pembrolizumab and Monoclonal Antibody Therapy in Advanced Cancer	Treatment	Cetuximab (DB00002) Pembrolizumab (DB09037) Trastuzumab (DB00072) Trastuzumab emtansine (DB05773)
NCT05091528	A Safety and Activity Study of SBT6050 in Combination With Other HER2-directed Therapies for HER2-positive Cancers	Treatment	Capecitabine (DB01101) Deruxtecan (DB22781) SBT6050 (DB29288) Trastuzumab (DB00072) Trastuzumab deruxtecan (DB14962) Tucatinib (DB11652)